Shi-Wen Huang

Shi-Wen Huang

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Biomaterials
Verified
Journal Article
Closed access
BWBo Wu
Bo Wu
SLShu-Ting Lu
Shu-Ting Lu
HYHui Yu
Hui Yu
RLRu-Fang Liao
Ru-Fang Liao
HLHuan Li
Huan Li
ZCZhen Cheng
Zhen Cheng

4 October 2017 in Nanoscale
Verified
Journal Article
Closed access
PDF file
WZWei Zhou
Wei Zhou
HYHui Yu
Hui Yu
LZLiu-Jie Zhang
Liu-Jie Zhang
BWBo Wu
Bo Wu
CWCai-Xia Wang
Cai-Xia Wang
SHShi-Wen Huang
Shi-Wen Huang
The importance of mitochondrial delivery of an anticancer drug to cancer cells has been recognized to improve therapeutic efficacy. The introduction of lipophilic cations, such as triphenylphosphonium (TPP), onto the surface of nanocarriers was utilized to target mitochondria via strong electrostatic interactions between positively charged TPP and the negatively charged mitochondrial membrane. However, the highly positive charge nature of TPP leads to rapid clearance from the blood, decrease of circulation lifetime, and nonspecific targeting of mitochondria of cells. Here, we report a strategy for improving the anticancer efficacy of paclitaxel via redox triggered intracellular activation of mitochondria-targeting. The lipid–polymer hybrid nanoparticles (LPNPs) are composed of poly(D,L-lactide-co-glycolide) (PLGA), a TPP-containing amphiphilic polymer (C18-PEG2000-TPP) and a reduction-responsive amphiphilic polymer (DLPE-S-S-mPEG4000). The charges of TPP in LPNPs were almost completely shielded by surface coating of a PEG4000 layer, ensuring high tumor accumulation. After uptake by cancer cells, the surface charges of LPNPs were recovered due to the detachment of PEG4000 under intracellular reductive conditions, resulting in rapid and precise localization in mitochondria. This kind of simple, easy and practicable mitochondria-targeting nanoplatform showed high anticancer activity, and the activatable strategy is valuable for developing a variety of nanocarriers for application in the delivery of other drugs.

1 March 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
NPNa Peng
Na Peng
HYHui Yu
Hui Yu
WYWenjie Yu
Wenjie Yu
MYMian Yang
Mian Yang
HCHongxiang Chen
Hongxiang Chen
Yi LiuYi Liu
Yi Liu

26 September 2018 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
QWQian Wang
Qian Wang
JLJia-Mi Li
Jia-Mi Li
HYHui Yu
Hui Yu
KDKai Deng
Kai Deng
WZWei Zhou
Wei Zhou
SHShi-Wen Huang
Shi-Wen Huang
Photodynamic therapy (PDT) as an alternative choice of cancer treatment method has attracted increasing attention in the past few decades. A sufficient amount of oxygen is essential for the production of singlet oxygen (1O2) in successful PDT; however, hypoxia is a typical hallmark of cancer, which is one of the most important limitation factors of PDT. To overcome the hypoxic tumour microenvironment and achieve highly efficient photodynamic cancer therapy, herein, a photosensitizer Ce6-loaded fluorinated polymeric micelle (Ce6-PFOC-PEI-M) was constructed via the self-assembly of an amphiphilic polymer prepared from perfluorooctanoic acid and branched polyethyleneimine (10 kDa). The introduction of perfluoroalkyl groups in the polymeric micelle Ce6-PFOC-PEI-M retained the oxygen-carrying capacity similar to perfluorocarbon, increased the oxygen level and overcame the hypoxia in C6 glioma cells under oxygen-deficient conditions. As a control, Ce6-OC-PEI-M without a perfluoroalkyl group could not increase the oxygen level in C6 glioma cells under the same conditions. With laser irradiation, Ce6-PFOC-PEI-M generated much more reactive oxygen species (ROS) in C6 glioma cells than Ce6-OC-PEI-M, leading to a higher phototoxicity in vitro and photodynamic tumour growth inhibition in vivo than Ce6-OC-PEI-M. Furthermore, there were no differences in the contents of Ce6 in tumour tissue between Ce6-PFOC-PEI-M and Ce6-OC-PEI-M. The higher efficacy of Ce6-PFOC-PEI-M in PDT is ascribed to its oxygen-carrying ability rather than higher content of Ce6 in the tumour. The presented fluorinated polymeric micelle could provide a new platform in the delivery of various photosensitizers and has great potential to improve the efficacy of PDT cancer therapy.

1 January 2019 in Theranostics
Verified
Journal Article
Open access
HYHui Yu
Hui Yu
JLJia-Mi Li
Jia-Mi Li
KDKai Deng
Kai Deng
WZWei Zhou
Wei Zhou
CWCai-Xia Wang
Cai-Xia Wang
SHShi-Wen Huang
Shi-Wen Huang
The drug resistance in cancer treatment with DOX is mainly related to the overexpression of drug efflux proteins, residing in the plasma and nuclear membranes. Delivering DOX into the mitochondria, lacking drug efflux proteins, is an interesting method to overcome DOX resistance. To solve the problem of positively charged triphenylphosphonium (TPP) for mitochondrial targeting in vivo, a charge reversal strategy was developed.

1 March 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
BWBo Wu
Bo Wu
SLShu-Ting Lu
Shu-Ting Lu
LZLiu-Jie Zhang
Liu-Jie Zhang
RZRen-Xi Zhuo
Ren-Xi Zhuo
HXHaibo Xu
Haibo Xu
SHShi-Wen Huang
Shi-Wen Huang
Codelivery is a promising strategy to overcome the limitations of single chemotherapeutic agents in cancer treatment. Despite progress, codelivery of two or more different functional drugs to increase anticancer efficiency still remains a challenge. Here, reduction-sensitive lipid–polymer hybrid nanoparticles (LPNPs) drug delivery system composed of monomethoxy-poly(ethylene glycol)-S-S-hexadecyl (mPEG-S-S-C16), soybean lecithin, and poly(d,l-lactide-co-glycolide) (PLGA) was used for codelivery of doxorubicin (DOX) and a Chinese herb extract triptolide (TPL). Hydrophobic DOX and TPL could be successfully loaded in LPNPs by self-assembly. More importantly, drug release and cellular uptake experiments demonstrated that the two drugs were reduction sensitive, released simultaneously from LPNPs, and taken up effectively by the tumor cells. DOX/TPL-coloaded LPNPs (DOX/TPL-LPNPs) exhibited a high level of synergistic activation with low combination index (CI) in vitro and in vivo. Moreover, the highest synergistic therapeutic effect was achieved at the ratio of 1:0.2 DOX/TPL. Further experiments showed that TPL enhanced the uptake of DOX by human oral cavity squamous cell carcinoma cells (KB cells). Overall, DOX/TPL-coencapsulated reduction-sensitive nanoparticles will be a promising strategy for cancer treatment.